Selfapy brings pharma partner MEDICE on board as investor

Berlin — The Berlin-based company Selfapy, which offers people with mental illnesses effec­tive help in the form of digi­tal health appli­ca­ti­ons, has gained a strong part­ner in Medice Arznei­mit­tel as an inves­tor. The tran­sac­tion was supported by the invest­ment bank Bryan, Garnier & Co. On Decem­ber 23, 2022, a finan­cing round of 7 million euros was nota­ri­zed in Berlin. Leading the pack was Medice Arznei­mit­tel, a family-owned phar­maceu­ti­cal company focu­sed on the treat­ment of ADHD. All exis­ting inves­tors were also invol­ved, inclu­ding the health­care inves­tor SHS, Think.Health Ventures, IBB Ventures and HTGF.

7 million for further growth in Germany and Europe

“The funding round is an important mile­stone and a confir­ma­tion of confi­dence in the success of Selfapy,” Nora Blum, Co-CEO and Foun­der of Selfapy. The capi­tal provi­ded is to be used for the deve­lo­p­ment of further digi­tal health appli­ca­ti­ons for various mental disor­ders and for growth in the German market. More doctors and psycho­the­ra­pists can now be infor­med by Selfapy about the bene­fits of DiGA and prescribe Selfapy’s therapy cour­ses to their mentally ill patients.

A further part of the capi­tal is to be used for market entry in other Euro­pean countries:

“We see great poten­tial for digi­tal thera­pies in the area of mental illness, both in Germany and inter­na­tio­nally. With five comple­ted RCT studies and a broad user base in Germany, we are well on our way to expand our offe­ring to other indi­ca­ti­ons and into other markets,” Adham Kassab, Co-CEO of Selfapy

“Selfapy’s strong perfor­mance over the past few years speaks for itself. Digi­tal health appli­ca­ti­ons will conti­nue to gain importance in the coming years. We conti­nue to see a lot of growth poten­tial here and look forward to accom­pany­ing Selfapy on this jour­ney,” Dr. Richard Ammer, CEO of Medice. — Today, the MEDICE Group is one of the most successful owner-mana­­ged family compa­nies in the German phar­maceu­ti­cal indus­try, with more than 1,000 employees and annual sales of over 300 million EURO in around 50 markets worldwide.

New digi­tal health apps for people with mental illnesses
Since 2021, Selfapy’s perma­nently listed online cour­ses for people with depres­sion and anxiety disor­ders have alre­ady been reim­bur­sed by all health insu­r­ers. The back­ground to this is the certi­fi­ca­tion of the therapy cour­ses as digi­tal health appli­ca­ti­ons (DiGA), which are perma­nently listed in the direc­tory of the Fede­ral Minis­try for Drugs and Medi­cal Devices (BfArM). The on the
Selfapy online cour­ses based on cogni­tive beha­vi­oral therapy methods signi­fi­cantly reduce the symptoms of people with depres­sion and gene­ra­li­zed anxiety disor­der: the effec­ti­ve­ness has been proven in rando­mi­zed control­led trials. Just a few weeks ago, Selfapy was able to offer two more online cour­ses for people with binge-eating disor­der and bulimia
Nervosa to its port­fo­lio, making it the first DiGA provi­der for eating disor­ders. But the total of four certi­fied online cour­ses is not to be the end of the story: The capi­tal raised will be used to deve­lop further digi­tal health appli­ca­ti­ons and to conduct addi­tio­nal clini­cal studies. www.selfapy.com